BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

BTIG analyst Julian Harrison has reiterated a Buy rating on Nektar Therapeutics (NASDAQ: NKTR) and maintained a price target of $178 for the stock. No additional financial figures or strategic changes were mentioned in the article.